Compare SMID & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | TNYA |
|---|---|---|
| Founded | 1960 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 181.5M |
| IPO Year | 1996 | 2021 |
| Metric | SMID | TNYA |
|---|---|---|
| Price | $29.50 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 12.7K | ★ 2.7M |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | 54.96 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $93,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $116.49 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.60 | $0.53 |
| 52 Week High | $43.62 | $2.35 |
| Indicator | SMID | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 54.78 |
| Support Level | $28.00 | $0.65 |
| Resistance Level | $36.29 | $0.94 |
| Average True Range (ATR) | 1.28 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 21.33 | 54.70 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.